Population Pharmacokinetics and Exposure-Response Analyses for Venetoclax in Combination with R-CHOP in Relapsed/Refractory and Previously Untreated Patients with Diffuse Large B Cell Lymphoma
Divya Samineni, Weize Huang, Leonid Gibiansky, Hao Ding, Rong Zhang, Chunze Li, Arijit Sinha, Richa Rajwanshi, Kathryn Humphrey, Alexandra Bazeos, Ahmed Hamed Salem, Dale Miles, Divya Samineni, Weize Huang, Leonid Gibiansky, Hao Ding, Rong Zhang, Chunze Li, Arijit Sinha, Richa Rajwanshi, Kathryn Humphrey, Alexandra Bazeos, Ahmed Hamed Salem, Dale Miles
Abstract
Introduction: Outcomes remain poor in patients with diffuse large B cell lymphoma (DLBCL) who overexpress BCL-2 protein. We present population pharmacokinetics (PopPK) and exposure-response (ER) analyses for venetoclax (a selective BCL-2 inhibitor) administered with rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with relapsed/refractory (R/R) and previously untreated (1L) non-Hodgkin lymphoma (NHL) from the phase 1b/2 CAVALLI study, to confirm dose selection for future studies.
Methods: Analyses included 216 patients with R/R or 1L NHL treated for eight 21-day cycles with 400-800 mg venetoclax (cycle 1: days 4-10; cycles 2-8: days 1-10) in combination with R for eight cycles and CHOP for 6-8 cycles. A legacy PopPK model for venetoclax was used to describe the observed data and provide post hoc PK parameters. Venetoclax steady-state exposure (AUCss) was used to predict clinical efficacy, safety, or tolerability. To isolate the effect of venetoclax, ER analyses referenced data from the R-CHOP arm of a historical control study, GOYA, in 1L DLBCL.
Results: There was no significant association between venetoclax AUCss and progression-free survival or complete response either for all-comers or the BCL-2-immunohistochemistry-positive subpopulation. No statistically significant trends were observed with venetoclax AUCss and the key grade ≥ 3 adverse events and serious adverse events. Similar dose intensities were observed for venetoclax and R-CHOP components across venetoclax exposures, suggesting venetoclax did not impact delivery of the R-CHOP backbone.
Conclusions: The PopPK and ER analyses, in addition to the positive benefit-risk observed in the clinical data, support the selection of 800 mg venetoclax given with R-CHOP for future studies in BCL-2-immunohistochemistry-positive patients with 1L DLBCL.
Trial registration: ClinicalTrials.gov Identifier NCT02055820.
Keywords: Diffuse Large B cell Lymphoma; Lymphoma; Pharmacokinetics; R-CHOP; Venetoclax.
© 2021. The Author(s).
Figures
References
- Hata AN, Yeo A, Faber AC, et al. Failure to induce apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and PI3K inhibitors for KRAS-mutant lung cancers. Cancer Res. 2014;74(11):3146–3156. doi: 10.1158/0008-5472.CAN-13-3728.
- Campbell KJ, Tait SWG. Targeting BCL-2 regulated apoptosis in cancer. Open Biol. 2018 doi: 10.1098/rsob.180002.
- Zhang HW, Cheng NL, Chen ZW, Wang JF, Li SH, Bai W. Clinical impact of t(14;18) in diffuse large B-cell lymphoma. Chin J Cancer Res. 2011;23(2):160–164. doi: 10.1007/s11670-011-0160-x.
- Anderson MA, Tsui A, Wall M, Huang DC, Roberts AW. Current challenges and novel treatment strategies in double hit lymphomas. Ther Adv Hematol. 2016;7(1):52–64. doi: 10.1177/2040620715608091.
- Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19(2):202–208. doi: 10.1038/nm.3048.
- Deeks ED. Venetoclax: first global approval. Drugs. 2016;76(9):979–987. doi: 10.1007/s40265-016-0596-x10.1007/s40265-016-0596-x.
- Venclexta (venetoclax) [package insert]. North Chicago, IL: AbbVie Inc; 2020.
- Davids MS, Roberts AW, Seymour JF, et al. Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-hodgkin lymphoma. J Clin Oncol. 2017;35(8):826–833. doi: 10.1200/JCO.2016.70.4320.
- Zelenetz AD, Salles G, Mason KD, et al. Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial. Blood. 2019 doi: 10.1182/blood-2018-11-880526.
- Vitolo U, Trneny M, Belada D, et al. Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma. J Clin Oncol. 2017;35(31):3529–3537. doi: 10.1200/JCO.2017.73.3402.
- Franck Morschhauser F, Feugier P, Flinn IW, et al. A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma. Blood. 2021;137(5):600–609. doi: 10.1182/blood.2020006578.
- Zelenetz AD, Feugier P, Flinn, I et al. Improved outcomes with venetoclax plus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in previously untreated patients with BCL-2-positive diffuse large B-cell lymphoma (DLBCL): updated desults from the phase II CAVALLI Study. (Abstract). 61st ASH Annual meeting; December 7−10. Orlando, Florida. 2019
- Jones AK, Freise KJ, Agarwal SK, Humerickhouse RA, Wong SL, Salem AH. Clinical predictors of venetoclax pharmacokinetics in chronic lymphocytic leukemia and non-hodgkin’s lymphoma patients: a pooled population pharmacokinetic analysis. AAPS J. 2016;18(5):1192–1202. doi: 10.1208/s12248-016-9927-9.
- Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13(2):143–151. doi: 10.1208/s12248-011-9255-z.
- Brendel K, Comets E, Laffont C, Laveille C, Mentre F. Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide. Pharm Res. 2006;23(9):2036–2049. doi: 10.1007/s11095-006-9067-5.
- Yano Y, Beal SL, Sheiner LB. Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check. J Pharmacokinet Pharmacodyn. 2001;28(2):171–192. doi: 10.1023/A:1011555016423.
- Beal S, Sheiner LB, Boeckmann A, Bauer RJ. NONMEM User’s Guides (1989–2011). Ellicott City, MD, USA: Icon Development Solutions; 2011
- Salem AH, Agarwal SK, Dunbar M, et al. Effect of low- and high-fat meals on the pharmacokinetics of venetoclax, a selective first-in-class BCL-2 inhibitor. J Clin Pharmacol. 2016;56(11):1355–1361. doi: 10.1002/jcph.741.
- Deng R, Gibiansky L, Lu T, et al. Bayesian population model of the pharmacokinetics of venetoclax in combination with rituximab in patients with relapsed/refractory chronic lymphocytic leukemia: results from the phase III MURANO study. Clin Pharmacokinet. 2019 doi: 10.1007/s40262-019-00788-8.
- Agarwal S, Gopalakrishnan S, Mensing S, et al. Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: an exposure-response analysis. Hematol Oncol. 2019 doi: 10.1002/hon.2646.
- Freise KJ, Dunbar M, Jones AK, et al. Venetoclax does not prolong the QT interval in patients with hematological malignancies: an exposure-response analysis. Cancer Chemother Pharmacol. 2016;78(4):847–853. doi: 10.1007/s00280-016-3144-1.
- Freise KJ, Jones AK, Menon RM, et al. Relationship between venetoclax exposure, rituximab coadministration, and progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergy. Hematol Oncol. 2017;35(4):679–684. doi: 10.1002/hon.2373.
- Freise KJ, Jones AK, Verdugo ME, Menon RM, Maciag PC, Salem AH. Moving beyond maximum tolerated dose for targeted oncology drugs: use of clinical utility index to optimize venetoclax dosage in multiple myeloma patients. Clin Pharmacol Ther. 2017;102(6):970–976. doi: 10.1002/cpt.712.
- Parikh A, Gopalakrishnan S, Freise KJ, et al. Exposure-response evaluations of venetoclax efficacy and safety in patients with non-Hodgkin lymphoma. Leuk Lymphoma. 2018;59(4):871–879. doi: 10.1080/10428194.2017.1361024.
- Choi YW, Jeong SH, Ahn MS, et al. Patterns of neutropenia and risk factors for febrile neutropenia of diffuse large B-cell lymphoma patients treated with rituximab-CHOP. J Korean Med Sci. 2014;29(11):1493–1500. doi: 10.3346/jkms.2014.29.11.1493.
- Hyman DM, Eaton AA, Gounder MM, et al. Predictors of early treatment discontinuation in patients enrolled on phase I oncology trials. Oncotarget. 2015;6(22):19316–19327. doi: 10.18632/oncotarget.2909.
- Matzdorff A, Meyer O, Ostermann H, et al. Immune thrombocytopenia—current diagnostics and therapy: recommendations of a joint working group of DGHO, OGHO, SGH, GPOH, and DGTI. Oncol Res Treat. 2018;41(Suppl 5):1–30. doi: 10.1159/000492187.
- Pfreundschuh M. How I treat elderly patients with diffuse large B-cell lymphoma. Blood. 2010;116(24):5103–5110. doi: 10.1182/blood-2010-07-259333.
- Davies A, Berge C, Boehnke A, et al. Subcutaneous rituximab for the treatment of B-cell hematologic malignancies: a review of the scientific rationale and clinical development. Adv Ther. 2017;34(10):2210–2231. doi: 10.1007/s12325-017-0610-z.
- Salles G, Barrett M, Foà R, et al. Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience. Adv Ther. 2017;34(10):2232–2273. doi: 10.1007/s12325-017-0612-x.
Source: PubMed